|
|
The Vascular Wall and Diabetes
|
|
|
|
Relativerisksforfatalcoronaryheartdiseaseinmenandwomenwithandwithoutdiabetes(meta-analysisof22prospectivecohortstudies
|
|
|
|
Diabetes – A Vascular Disease
|
|
|
|
PutativeMechanismsforAcceleratedAtherosclerosisinType2Diabetes
|
|
|
|
Transverse section of LAD from a 72 year old type 2 DM
|
|
|
|
Non-enzymatic Glycation
|
|
|
|
FormationofAdvancedGlycationEndProducts
|
|
|
|
Formation of AGEs
|
|
|
|
Advanced Glycation End Products
|
|
|
|
IncreasedserumAGEspredictscardiovascularmortalityintype2DM
|
|
|
|
AGELevelsinSkinCollagenPredicttheRiskofFuture10-YearProgressionofDiabeticNephropathyintheDCCT/EDICStudy
|
|
|
|
Advanced Glycation End Products and Atherosclerosis
|
|
|
|
Non-receptor-mediated effects of AGEs on atherogenesis
|
|
|
|
Decrease vascular compliance in type 2 diabetes
|
|
|
|
AGEs and Decreased Vascular Compliance in Diabetes
|
|
|
|
AGEcross-linkbreakersreducelargearterystiffness
|
|
|
|
Formation of AGEs on plasma lipoproteins
|
|
|
|
FormationofAGEsinglycoxidizedLDLinvitro
|
|
|
|
IncreasedapoB-CMLintype2DM
|
|
|
|
Biological Effects of AGE-modified LDL
|
|
|
|
AGEs Potentiate the Atherogenic Effects of Dyslipidaemia in Diabetes
|
|
|
|
Advanced Glycation End Products and Atherosclerosis
|
|
|
|
Structure of full-length RAGE and its splice variants
|
|
|
|
Endothelialdysfunctionintype2diabetes
|
|
|
|
AGEandImpairedEndothelium-dependentVasodilationinDiabetes
|
|
|
|
AGEsReducesNOProductionbyDown-regulationofEndothelialNitricOxideSynthase
|
|
|
|
EffectofAGE-BSAoneNOSBlockedbyAnti-RAGEAntibody
|
|
|
|
Dia 28
|
|
|
|
Therapeutic options
|
|
|
|
Advanced Glycation End Product Interventions Reduce Diabetes-Accelerated Atherosclerosis
|
|
|
|
Atheroscleroticplaqueareaattenuatedby30%withALT-711andby40%inAG-treatedmice
|
|
|
|
BlockadeofAGE-RAGEaxiswithsRAGEsuppressesprogressionofestablishedatherosclerosisinapoE-nullmice
|
|
|
|
PharmacologicalModulationofsRAGE
|
|
|
|
Type2DMrandomisedtoreceiveadd-ontherapywithrosiglitazoneorsulphonylurea
|
|
|
|
Type 2 DM randomised to atorvastatin or placebo
|
|
|
|
Pharmacological modulation of soluble RAGE
|
|
|
|
Endothelialdysfunctionandvascularinflammation
|
|
|
|
Acknowledgement
|
|
Share this page with your colleagues and friends: